Stock Price & Analysis

Based on the provided data and recent analyst updates, here's a concise analysis of DGX's current position:

Technical Analysis

The stock shows moderate bullish momentum with an RSI of 64.41, indicating room for further upside while not being overbought. The MACD is positive at 2.76, suggesting positive momentum.

Recent Analyst Actions Several analysts have recently updated their price targets:

• Piper Sandler: $180 (Hold)
• Barclays: $175 (Hold)
• Bank of America: Maintains Buy

Fundamental Strength The company demonstrated solid Q4 2024 performance with:

• Revenue: $2.62B
• Net Income: $220M
• Gross Margin: 31.71%
• Net Margin: 9%

Valuation Metrics

Current valuation metrics show:

• P/E: 19.68x
• EV/EBITDA: 11.86x
• Dividend Yield: 1.99%

Based on the technical momentum, strong fundamentals, and recent analyst upgrades, DGX appears to be a hold at current levels. The stock has support from multiple analysts with price targets in the $175-180 range, suggesting about 10% upside potential from current levels.

Based on recent analyst reports and technical indicators, DGX stock is projected to reach $182-190 by end of 2025, supported by multiple analysts raising price targets. The bullish outlook is driven by Quest Diagnostics' strong organic revenue growth of 5% and expansion into higher-margin testing areas. Technical analysis shows an RSI of 64.41 indicating moderate upward momentum while staying above the 20-day moving average of $157.62, suggesting continued positive price action.

The S1 support level for DGX Stock is $161.12 ,The R1 resistant level for DGX Stock is $169.75.

As of the end of day on 2025-02-14, the price of DGX Stock was $168.77.

The target price for DGX Stock according to analyst rating is 180.42, with the highest price target at 190.00 and the lowest at 170.00. Analysts have a Moderate Buy rating on DGX Stock overall.

The market cap of DGX is $18.7B.

Based on the provided data, here's a concise analysis of DGX's valuation:

Valuation Analysis: Quest Diagnostics currently trades at a P/E ratio of 19.68x, which is slightly elevated compared to its historical range of 17.83x-20.65x in 2024. The EV/EBITDA ratio stands at 11.86x, showing moderate valuation levels.

Financial Performance: The company has demonstrated stable revenue growth from $2.37B to $2.62B over recent quarters, with consistent net margins around 9-10%. The gross margin has remained steady at approximately 31-32%.

Market Position: Recent analyst coverage shows a positive sentiment, with Piper Sandler raising the price target to $180 from $165, citing growth in higher-margin testing areas. The consensus among analysts suggests a "Moderate Buy" rating.

Conclusion: Based on current metrics, DGX appears slightly overvalued when considering its P/E ratio trending near the upper end of its recent range, moderate EV/EBITDA multiple, and relatively stable but not exceptional growth rates in key financial metrics.

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.

Based on recent analyst reports and market data, Quest Diagnostics (DGX) stock is projected to reach $210-230 by 2030, driven by expansion into high-margin testing areas and strong organic revenue growth of 5%. The company's strategic focus on advanced diagnostic technologies and M&A activities provides attractive tailwinds for long-term growth. Multiple analyst upgrades in early 2025, including price targets of $180-190, indicate strong market confidence in DGX's business model and future prospects.

DGX has a total of 40000 employees.